3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
8
Neoplasms
4
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
13
Gemcitabine
10
Ifosfamide
9
Trabectedin
7
Radiotherapy
7
Docetaxel
5
Dacarbazine
5
pazopanib
3
Sunitinib
3
Sorafenib
3
Nivolumab
3
Filgrastim
3
pembrolizumab
2
pegfilgrastim
2
liposomal doxorubicin
2
eribulin
2
cixutumumab
2
belinostat
2
Radiotherapy, Conformal
2
Imatinib Mesylate
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
tremelimumab
1
temsirolimus
1
soblidotin
1
selinexor
1
sargramostim
1
saracatinib
1
rubitecan
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leiomyosarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts